The rise of Sildenafil initially drove a period of growth for major pharmaceutical companies, but recent changes present a uncertain scenario for shareholders. Off-patent competitors are eroding earnings, and continued https://teganlzca154081.bloguerosa.com/39859707/the-blue-pill-and-pharma-a-volatile-bet